1
|
Gerlach M, Schmitt S, Cyprys P, Kasper MA, Mai I, Vermeer MH, Horwitz SM, Fingerle-Rowson G, Vogl A, Schumacher D, Helma-Smets J. TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00604-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
2
|
Huth S, Huth L, Heise R, Marquardt Y, Fingerle-Rowson G, Boor P, Yazdi A, Bernhagen J, Baron J. 259 Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB, but not chemically induced non-melanoma skin cancer. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Stark K, Pekayvaz K, Hoseinpour P, Coletti R, Gold C, Ishikawa-Ankerhold H, Lorenz M, Fingerle-Rowson G, Bucala R, Schulz C, Massberg S. 4148Activation of canonical proinflammatory pathways in smooth muscle cells exerts paradoxical atheroprotective effects. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.4148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Stark
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - K Pekayvaz
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - P Hoseinpour
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - R Coletti
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - C Gold
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | | | - M Lorenz
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - G Fingerle-Rowson
- University of Cologne, Department I of Internal Medicine, Cologne, Germany
| | - R Bucala
- Yale University, Department of Internal Medicine, New Haven, United States of America
| | - C Schulz
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| | - S Massberg
- Ludwig-Maximilians University, Medizinische Klinik I, Munich, Germany
| |
Collapse
|
4
|
Trotman J, Barrington S, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Hiddemann W, Marcus R, Davies A. PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Trotman
- Haematology Department; Concord Repatriation General Hospital; Sydney Australia
| | - S. Barrington
- KCL and Guys' & St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering; Kings College London; London UK
| | - D. Belada
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, and Charles University in Prague; Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - M. Meignan
- Service de Médecine Nucléaire; Hôpital Henri Mondor and Université Paris Est Créteil; Créteil France
| | - R. MacEwan
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - C. Owen
- Division of Hematology and Hematological Malignancies; Foothills Medical Centre and Tom Baker Cancer Centre; Calgary Canada
| | - V. Ptáčník
- Department of Nuclear Medicine, First Faculty of Medicine; Charles University; Prague Czech Republic
| | - A. Rosta
- Department of Medicine; National Institute of Oncology; Budapest Hungary
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
5
|
Kostakoglu L, Martelli M, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Sehn L, Shi Y, Tatsumi Y, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Vitolo U, Trněný M. END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_45] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Kostakoglu
- Department of Radiology; Icahn School of Medicine at Mount Sinai; New York USA
| | - M. Martelli
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital Hradec Kralove, and Charles University in Prague, Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - A.M. Carella
- U.O. Hematology I; IRCCS AO University, San Martino-IST; Genoa Italy
| | - N. Chua
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - E. Gonzalez-Barca
- Institut Catalá d'Oncologia Hospitalet, IDIBELL; University of Barcelona; Barcelona Spain
| | - X. Hong
- Department of Medical Oncology; Fudan University Shanghai Cancer Center; Shanghai China
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale; IRCCS; Naples Italy
| | - L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency and the University of British Columbia; Vancouver Canada
| | - Y. Shi
- National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Beijing China
| | - Y. Tatsumi
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Trněný
- Department of Medicine-Department of Hematology; Charles University; Prague Czech Republic
| |
Collapse
|
6
|
Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, Rosta A, Schmidt P, Trněný M, Burciu A, Fingerle-Rowson G, Rufibach K, Zeuner H, Hiddemann W, Marcus R. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_136] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Herold
- Oncology Center, HELIOS-Klinikum Erfurt; Erfurt Germany
| | - E. Hoster
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - A. Janssens
- Department of Haematology; UZ Leuven; Leuven Belgium
| | - H. McCarthy
- Department of Haematology; Royal Bournemouth General Hospital; Bournemouth UK
| | - A. Tedeschi
- Division of Hematology; A. O. Ospedale Niguarda Ca’ Granda; Milan Italy
| | - C. Pocock
- Department of Haematology; Kent & Canterbury Hospital; Canterbury UK
| | - A. Rosta
- Department of Haematology, Országos Onkológiai Intézet; Budapest Hungary
| | - P. Schmidt
- Dr. med. Peter Schmidt; Praxis Neunkirchen/Saar Germany
| | - M. Trněný
- 1st Department of Medicine; Charles University General Hospital; Prague Czech Republic
| | - A. Burciu
- Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - K. Rufibach
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - H. Zeuner
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| |
Collapse
|
7
|
Sehn L, Oestergaard M, Trněný M, Bosi A, Egyed M, Illes A, Nakamae H, Opat S, Topp M, Zaja F, Fingerle-Rowson G, Lei G, Nielsen T, Punnoose E, Rahman M, Ray J, Zhang L, Martelli M, Vitolo U. PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_121] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency and the University of British Columbia; Vancouver Canada
| | - M.Z. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Trněný
- Charles University; General Hospital; Prague Czech Republic
| | - A. Bosi
- Department of Hematology; Azienda Ospedaliero Universitaria Careggi; Florence Italy
| | - M. Egyed
- Department of Hematology; Kaposi Mor Teaching Hospital; Kaposvár Hungary
| | - A. Illes
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - H. Nakamae
- Department of Hematology; Osaka City University Hospital; Osaka Japan
| | - S. Opat
- Department of Clinical Haematology; Monash Health and Monash University; Melbourne Australia
| | - M. Topp
- Department of Haematology, Medizinische Klinik und Poliklinik II; Universitätsklinikum Würzburg; Würzburg Germany
| | - F. Zaja
- Department of Hematology, ASUIUD S. M. Misericordia; Udine Italy
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Lei
- Department of Biostatistics, Roche Products Ltd; Welwyn Garden City UK
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - E.A. Punnoose
- Oncology Biomarker Development; Genentech Inc.; South San Francisco USA
| | - M. Rahman
- Department of Biostatistics, Roche Products Ltd; Welwyn Garden City UK
| | - J. Ray
- Oncology Biomarker Development; Genentech Inc.; South San Francisco USA
| | - L. Zhang
- Department of Pathology; Ventana Medical Systems Inc.; Tucson USA
| | - M. Martelli
- Department of Cellular Biotechnologies and Haematology; Sapienza University; Rome Italy
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| |
Collapse
|
8
|
Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia 2013; 27:1949-52. [PMID: 23787395 PMCID: PMC3768112 DOI: 10.1038/leu.2013.190] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
9
|
Schmitt S, Goldschmidt H, Storch-Hagenlocher B, Pham M, Fingerle-Rowson G, Ho AD, Neben K. Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol 2011; 93:791-794. [DOI: 10.1007/s12185-011-0847-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Revised: 03/30/2011] [Accepted: 03/30/2011] [Indexed: 10/18/2022]
|
10
|
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74. [PMID: 20888994 DOI: 10.1016/s0140-6736(10)61381-5] [Citation(s) in RCA: 1269] [Impact Index Per Article: 90.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. METHODS Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on day 1 of second to sixth courses) in 190 centres in 11 countries. Investigators and patients were not masked to the computer-generated treatment assignment. The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00281918. FINDINGS 408 patients were assigned to fludarabine, cyclophosphamide, and rituximab (chemoimmunotherapy group) and 409 to fludarabine and cyclophosphamide (chemotherapy group); all patients were analysed. At 3 years after randomisation, 65% of patients in the chemoimmunotherapy group were free of progression compared with 45% in the chemotherapy group (hazard ratio 0·56 [95% CI 0·46-0·69], p<0·0001); 87% were alive versus 83%, respectively (0·67 [0·48-0·92]; p=0·01). Chemoimmunotherapy was more frequently associated with grade 3 and 4 neutropenia (136 [34%] of 404 vs 83 [21%] of 396; p<0·0001) and leucocytopenia (97 [24%] vs 48 [12%]; p<0·0001). Other side-effects, including severe infections, were not increased. There were eight (2%) treatment-related deaths in the chemoimmunotherapy group compared with ten (3%) in the chemotherapy group. INTERPRETATION Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia. Moreover, the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytic leukaemia. FUNDING F Hoffmann-La Roche.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/administration & dosage
- Disease Progression
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Immunologic Factors/administration & dosage
- Incidence
- Kaplan-Meier Estimate
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukopenia/chemically induced
- Male
- Middle Aged
- Neutropenia/chemically induced
- Rituximab
- Severity of Illness Index
- Treatment Outcome
- Vidarabine/administration & dosage
- Vidarabine/analogs & derivatives
Collapse
Affiliation(s)
- M Hallek
- Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kleemann R, Verschuren L, Wielinga P, Voshol P, van Erk M, Fingerle-Rowson G, Willems van Dijk K, Ouwens M, Bernhagen J, Bucala R, Kooistra T. P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70148-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009; 23:2007-17. [PMID: 19641522 DOI: 10.1038/leu.2009.140] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Rituximab-containing regimens are becoming a therapeutic standard in chronic lymphocytic leukemia (CLL), so that a validation of flow cytometric minimal residual disease (MRD) quantification (MRD flow) in the presence of this antibody is necessary. We therefore compared results obtained by real-time quantitative (RQ)-PCR to MRD flow in 530 samples from 69 patients randomized to receive chemotherapy or chemotherapy plus rituximab. Quantitative MRD levels assessed by both techniques were closely correlated irrespective of therapy (r=0.95). The sensitivity and specificity of MRD flow was not influenced by the presence of rituximab. With 58.9% positive and 26.4% negative samples by both techniques, 85.3% of assessments (452/530) were qualitatively concordant between MRD flow and RQ-PCR. Discordant samples were typically negative by MRD flow and simultaneously positive close to the detection limit of the PCR assays, indicating a higher sensitivity of PCR for very low MRD levels. However, 93.8% of all samples were concordantly classified by both methods using a threshold of 10(-4) to determine MRD positivity. MRD flow and PCR are equally effective for MRD quantification in rituximab-treated CLL patients within a sensitivity range of up to 10(-4), whereas PCR is more sensitive for detecting MRD below that level.
Collapse
Affiliation(s)
- S Böttcher
- Second Department of Medicine, University of Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Knop S, Liebisch P, Wandt H, Kropff M, Jung W, Kroeger N, Sezer O, Straka C, Fingerle-Rowson G, Einsele H. Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8516] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8516 Background: Cytoreductive induction followed by HD-MEL and ASCT is considered standard of care for younger patients (pts) with multiple myeloma (MM). The success of this combined procedure partially depends on the efficacy of induction treatment. Bortezomib-containing induction regimens have already been shown to be superior to standard VAD. In order to further improve the efficacy of induction treatment we combined Vel with intravenous (IV) cyclophosphamide (C) and dexamethasone (D). Methods: This trial is an open, prospective, multicenter, uncontrolled phase II/III study with a planned recruitment of 400 pts. The first 30 pts were included in the dose finding study to determine the optimum dose of IV C in conjunction with Vel and D. The following 170 pts up to 60 years of age with untreated MM were enrolled to receive 3 cycles of induction with Vel 1.3 mg/m2 IV d1, 4, 8, 11; D 40 mg/d d1, 2, 4, 5, 8, 9, 11, 12; and C 900mg/m2 IV d1. Primary study objective is response rate (≥ PR) to VelCD according to the EBMT criteria. Results: Data from the first completed 200 pts (mean age: 52 years; 74% stage III) from 36 German centers were analyzed as ITT population. Response rates are given in Table and were documented in 82% of the subjects with 13q-, in 94% with t(4;14) and in 70% with 17p-. SAEs (n=84) occurred in 24.5% of the pts and were related to Vel, C or D in 16%, 14.5% or 9.5% respectively. The mortality rate of 1% is low, 53% of the patients experienced grade 3 + 4 AEs, infections of grade 3 and 4 were reported in 2% and grade 3 paraesthesia occurred in 2%. Conclusions: This interim analysis demonstrates that bortezomib combined with dexamethasone and intravenous cyclophosphamide (VelCD) is a highly effective induction regimen for pts ≤ 60 years with newly diagnosed MM regardless of cytogenetic risk factors. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. Knop
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - P. Liebisch
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - H. Wandt
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - M. Kropff
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - W. Jung
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - N. Kroeger
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - O. Sezer
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - C. Straka
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - G. Fingerle-Rowson
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| | - H. Einsele
- University Hospital, Wuerzburg, Germany; University Hospital, Ulm, Germany; Klinikum Nord, Nuremberg, Germany; University of Muenster, Muenster, Germany; University Hospital, Goettingen, Germany; University Hospital Eppendorf, Hamburg, Germany; University Hospital Charite, Berlin, Germany; Clinic Dr. Argirov, Berg, Germany; Janssen-Cilag, Neuss, Germany
| |
Collapse
|
14
|
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Lüscher B, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26:5046-59. [PMID: 17310986 DOI: 10.1038/sj.onc.1210318] [Citation(s) in RCA: 274] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical inflammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized fibroblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF(-/-)MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in fibroblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.
Collapse
Affiliation(s)
- H Lue
- Department of Biochemistry and Molecular Cell Biology, Institute of Biochemistry, University Hospital RWTH Aachen, Aachen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Macrophage migration inhibitory factor (MIF) is a potent regulator of inflammation and cell growth. Using the Emu-Myc lymphoma mouse model, we demonstrate that loss of MIF markedly delays the onset of B-cell lymphoma development in vivo. The molecular basis for this MIF-loss-induced phenotype is the perturbed DNA-binding activity of E2F factors and the concomitantly enhanced tumor suppressor activity of the p53 pathway. Accordingly, premalignant MIF-null Emu-Myc B-cells are predisposed to delayed S-phase progression and increased apoptosis. MIF-deficient lymphomas that do arise under these conditions contain frequent ARF deletions and p53 inactivating mutations. Conversely, MIF expression is retained in tumors developed by wild-type Emu-Myc animals, and the presence of one or both MIF alleles is sufficient to accelerate the development of Myc-induced lymphomas. Collectively, these results indicate that MIF promotes Myc-mediated tumorigenesis, at least in the B-lymphoid compartment, and implicate MIF as a mediator of malignant cell growth in vivo.
Collapse
Affiliation(s)
- F Talos
- Department of Pathology, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
| | | | | | | | | |
Collapse
|
16
|
Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Döhner H, Kneba M, Emmerich B, Hallek M. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18:1093-101. [PMID: 15071604 DOI: 10.1038/sj.leu.2403354] [Citation(s) in RCA: 190] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Patients with CLL responding to initial chemotherapy with fludarabine alone (F) or in combination with cyclophosphamide (FC) were randomized for treatment with alemtuzumab (30 mg i.v. TIW, 12 weeks) or observation. Of 21 evaluable patients, 11 were randomized to alemtuzumab before the study was stopped due to severe infections in seven of 11 patients. These infections (one life-threatening pulmonary aspergillosis IV; four CMV reactivations III requiring i.v. ganciclovir; one pulmonary tuberculosis III; one herpes zoster III) were successfully treated and not associated with cumulative dose of alemtuzumab. In the observation arm, one herpes zoster infection II and one sinusitis I were documented. At 6 months after randomization, two patients in the alemtuzumab arm converted to CR, while three patients in the observation arm progressed. After alemtuzumab treatment, five of six patients achieved a molecular remission in peripheral blood while all patients in the observation arm remained MRD-positive (P=0.048). At 21.4 months median follow-up, patients receiving alemtuzumab showed a significant longer progression-free survival (no progression vs mean 24.7 months; P=0.036). In conclusion, a consolidation therapy with alemtuzumab is able to achieve molecular remissions and longer survival in CLL, but a safe treatment regimen needs to be determined.
Collapse
MESH Headings
- Adult
- Aged
- Alemtuzumab
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm/administration & dosage
- Antibodies, Neoplasm/adverse effects
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Disease-Free Survival
- Female
- Germany
- Humans
- Infections/etiology
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Neoplasm, Residual/drug therapy
- Neoplasm, Residual/mortality
- Neutropenia/chemically induced
- Remission Induction
Collapse
Affiliation(s)
- C-M Wendtner
- Klinikum Grosshadern, Medical Clinic III, Ludwig-Maximilians-University, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Müller W, Bucala R. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A 2003; 100:9354-9. [PMID: 12878730 PMCID: PMC170922 DOI: 10.1073/pnas.1533295100] [Citation(s) in RCA: 231] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Macrophage migration inhibitory factor (MIF) is a mediator of host immunity and functions as a high, upstream activator of cells within the innate and the adaptive immunological systems. Recent studies have suggested a potentially broader role for MIF in growth regulation because of its ability to antagonize p53-mediated gene activation and apoptosis. To better understand MIF's activity in growth control, we generated and characterized a strain of MIF-knockout (MIF-KO) mice in the inbred, C57BL/6 background. Embryonic fibroblasts from MIF-KO mice exhibit p53-dependent growth alterations, increased p53 transcriptional activity, and resistance to ras-mediated transformation. Concurrent deletion of the p53 gene in vivo reversed the observed phenotype of cells deficient in MIF. In vivo studies showed that fibrosarcomas induced by the carcinogen benzo[alpha]pyrene are smaller in size and have a lower mitotic index in MIF-KO mice relative to their WT counterparts. The data provide direct genetic evidence for a functional link between MIF and the p53 tumor suppressor and indicate an important and previously unappreciated role for MIF in carcinogenesis.
Collapse
Affiliation(s)
- G Fingerle-Rowson
- The Picower Institute for Medical Research, Manhasset, NY 11030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients]. MMW Fortschr Med 2003; 145:46-9. [PMID: 14587189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
MESH Headings
- Age Factors
- Aged
- Alemtuzumab
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antibodies, Neoplasm/therapeutic use
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- Bendamustine Hydrochloride
- Chlorambucil/administration & dosage
- Chlorambucil/therapeutic use
- Combined Modality Therapy
- Enzyme Inhibitors/administration & dosage
- Enzyme Inhibitors/therapeutic use
- Humans
- Immunosuppressive Agents/administration & dosage
- Immunosuppressive Agents/therapeutic use
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/radiotherapy
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Middle Aged
- Nitrogen Mustard Compounds/administration & dosage
- Nitrogen Mustard Compounds/therapeutic use
- Radiotherapy Dosage
- Randomized Controlled Trials as Topic
- Risk Factors
- Rituximab
- Time Factors
- Vidarabine/administration & dosage
- Vidarabine/analogs & derivatives
- Vidarabine/therapeutic use
Collapse
Affiliation(s)
- M Hallek
- Medizinische Klinik III, Klinikum, Universität München-Grosshadern.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Hallek M, Bergmann M, Wendtner CM, Fingerle-Rowson G, Schmitt B. Allogeneic stem cell transplantation in chronic lymphocytic leukemia: the con's. Ann Hematol 2003; 81 Suppl 2:S48-50. [PMID: 12611076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Affiliation(s)
- M Hallek
- Medizinische Klinik III, Klinikum, Universität München, Grosshadern, Germany
| | | | | | | | | |
Collapse
|
20
|
Fingerle-Rowson G, Auers J, Kreuzer E, Fraunberger P, Blumenstein M, Ziegler-Heitbrock LH. Expansion of CD14+CD16+ monocytes in critically ill cardiac surgery patients. Inflammation 1998; 22:367-79. [PMID: 9675608 DOI: 10.1023/a:1022316815196] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We have asked whether critically ill cardiac valve surgery patients identified by a high APACHE II score exhibit an increase in the number of proinflammatory CD14+CD16+ monocytes. A group of 12 patients was studied over a period of 5 days post cardiac valve surgery for changes in blood monocyte populations. Patients were selected on day 1 post surgery to either be in good clinical condition (APACHE II Score of < or = 14; N = 9) or to be critically ill (APACHE II score of > or = 24; N = 3). The < or = 14 patients had an uneventful course and could leave the ICU after 2-3 days. Among the > or = 24 patients two showed a decrease of the score to < or = 14 within the 5 days of observation and they could leave the ICU thereafter. One > or = 24 patient (patient #2) had a persistently high score and finally died on day 28. Analysis of blood monocytes on day 1 post surgery revealed that the < or = 14 patients had normal values of CD14+CD16+ monocytes (44 +/- 9/microliter). By contrast the > or = 24 patients had increased values of these cells with 243 +/- 106 cells per microliter on day 1. The numbers of CD14+CD16+ monocytes returned to the control range over the 5 days of observation in 2 of the > or = 24 patients concomitant with the improvement of the APACHE II score. CD14+CD16+ monocytes remained, however, at a high level in patient #2, the patient with persistently high APACHE II score.
Collapse
Affiliation(s)
- G Fingerle-Rowson
- Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, FRG
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
Glucocorticoids (GC) are potent anti-inflammatory and immunosuppressive agents that act on many cells of the body, including monocytes. Here we show that a 5-day course of high dose GC therapy differentially affected the CD14++ and the CD14+ CD16+ monocyte subpopulations in 10 patients treated for multiple sclerosis. While the classical (CD14++) monocytes exhibited a substantial increase from 495 +/- 132 to 755 +/- 337 cells/microl, the CD14+ CD16+ monocytes responded with a pronounced decrease from 36 +/- 15 to 2 +/- 3 cells/microl (P < 0.001). In 4/10 patients the CD14+ CD16+ monocytes fell below detection limits (<0.2 cells/microl). This observation was confirmed when the CD14+ CD16+ monocytes were identified by virtue of their low CD33 expression as these cells decreased as well. After discontinuation of GC therapy the CD14+ CD16+ monocytes reappeared and reached normal levels after 1 week. The profound depletion of CD14+ CD16+ monocytes by GC as described here is a novel effect of GC action in vivo and may contribute to GC-mediated immunosuppression. Determination of the number of this monocyte subset may also serve to monitor the effectiveness of GC therapy in patients requiring immunosuppressive treatment.
Collapse
Affiliation(s)
- G Fingerle-Rowson
- Department of Internal Medicine I, Klinikum Grosshadern, University of Munich, Germany
| | | | | | | |
Collapse
|
22
|
Fingerle-Rowson G, Auers J, Kreuzer E, Labeta M, Schmidt B, Samtleben W, Ziegler-Heitbrock HW, Blumenstein M. Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation. J Thorac Cardiovasc Surg 1998; 115:1172-8. [PMID: 9605088 DOI: 10.1016/s0022-5223(98)70418-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Major operative trauma like aorta-coronary bypass operation may lead to postoperative immunodisturbance, putting the patient at an increased risk for infection and sepsis. The monocyte/macrophage system and the endotoxin receptor CD14 are important in the early recognition and elimination of invading bacteria. The aim of this study was to analyze changes in membrane-associated CD14 and soluble CD14 during and after cardiac involving cardiopulmonary bypass. METHODS We studied numbers of leukocytes, monocytes, and monocyte subpopulations, expression of monocyte membrane-associated CD14 and plasma levels of soluble CD14 in 10 patients (63 +/- 8 years of age), who underwent elective cardiopulmonary bypass. RESULTS Cardiopulmonary bypass induced marked postoperative monocytosis, which was maximal 20 hours after the operation (485 +/- 242 cells/microl before, 1080 +/- 264 cells/microl 20 hours after surgery). Expression of membrane-associated CD14 on classical CD14++ monocytes decreased significantly by 40%, reaching a nadir 20 hours after surgery (p < 0.05). At the time of maximal membrane-associated CD14 suppression, the levels of soluble CD14 measured by enzyme-linked immunosorbent assay were clearly increased (3.2 +/- 1.0 microg/ml before versus 5.6 +/- 1.0 microg/ml 20 hours after, p < 0.001). No significant change of the percentage of small (alpha) and large (beta) forms of soluble CD14 was found. CONCLUSIONS Cardiopulmonary bypass leads to reduced membrane-associated CD14 expression on peripheral blood monocytes and increased levels of soluble CD14 through shedding or secretion of membrane-associated CD14 from the cell surface. These findings indicate that bypass is associated with significant monocyte activation.
Collapse
Affiliation(s)
- G Fingerle-Rowson
- Department of Internal Medicine I, Klinikum Grosshadern, University of Munich, München, Germany
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Blumenstein M, Boekstegers P, Fraunberger P, Andreesen R, Ziegler-Heitbrock HW, Fingerle-Rowson G. Cytokine production precedes the expansion of CD14+CD16+ monocytes in human sepsis: a case report of a patient with self-induced septicemia. Shock 1997; 8:73-5. [PMID: 9249916 DOI: 10.1097/00024382-199707000-00012] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We describe a patient with self-induced disease who presented with repeated urinary tract infection and sepsis due to intravesical and intravenous injection of feces. Sepsis occurred repeatedly such that the patient exhibited 10 bouts of fever > 40 degrees C in a single month. This bacterial challenge led to massive activation of the monocyte system with high levels of TNF-alpha, IL-6, and monocyte colony-stimulating factor (M-CSF). This cytokine response was followed by strong expansion of the novel CD14+CD16+ monocyte subset. These results suggest that cytokines induce the development of CD14+CD16+ cells in human septicemia and that CD14+CD16+ cells may serve as indicator for previous bouts of excessive inflammation.
Collapse
Affiliation(s)
- M Blumenstein
- Medical Department I, Grosshadern Hospital, Munich University, Germany
| | | | | | | | | | | |
Collapse
|